"July is migraine month" per 'drjwater' and he's right! (Not yet though on Buyout!)
July 1st and 2nd we've lost $0.26 per share, that is a headache 8.5% drop in two days on no NuPath news. We are $1.00 per share lower than the settled price after FDA approval, why own shares if this results after the coveted event of FDA approval happens? Management continues to dilute with their warrants, and we get nothing, no announcements, only speculation of no partner or buyout. Go it alone? Nah, no $. The value now is attractive, but I already have my risk tolerance position established and am not adding more when other names look more certain. GLTA longs, hope we can make something of this yet. The product and market potential keep me here.